TY - JOUR T1 - Best Practices for <sup>18</sup>F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists JF - Journal of Nuclear Medicine Technology JO - J. Nucl. Med. Technol. SP - 282 LP - 287 DO - 10.2967/jnmt.119.227116 VL - 47 IS - 4 AU - Funmilayo I. Tade AU - Rebecca A. Sajdak AU - Mehdat Gabriel AU - Robert H. Wagner AU - Bital Savir-Baruch Y1 - 2019/12/01 UR - http://tech.snmjournals.org/content/47/4/282.abstract N2 - 18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. 18F-fluciclovine PET/CT is performed significantly differently from 18F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the 18F-fluciclovine PET/CT protocol. ER -